These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 22357638)

  • 41. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of fulvestrant in clinical practice: use of an electronic data registry.
    Lower EE; Esparaz BT; Garnett SA; Wade JL
    Clin Breast Cancer; 2007 Apr; 7(7):565-9. PubMed ID: 17509166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fulvestrant revisited: efficacy and safety of the 500-mg dose.
    Howell A; Sapunar F
    Clin Breast Cancer; 2011 Aug; 11(4):204-10. PubMed ID: 21729658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.
    Diaby V; Adunlin G; Zeichner SB; Avancha K; Lopes G; Gluck S; Montero AJ
    Breast Cancer Res Treat; 2014 Sep; 147(2):433-41. PubMed ID: 25012857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The future of fulvestrant ("Faslodex").
    Howell A
    Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes.
    Orr RK; Col NF; Kuntz KM
    Surgery; 1999 Sep; 126(3):568-76. PubMed ID: 10486611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
    McCormack P; Sapunar F
    Clin Breast Cancer; 2008 Aug; 8(4):347-51. PubMed ID: 18757262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Half-dose fulvestrant plus anastrozole as a first-line treatment for hormone receptor-positive metastatic breast cancer: a cost-effectiveness analysis.
    Huang X; Weng X; Lin S; Liu Y; Luo S; Wang H; Ming WK; Huang P
    BMJ Open; 2020 Aug; 10(8):e036107. PubMed ID: 32868353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer.
    Howell A; Bergh J
    J Clin Oncol; 2010 Oct; 28(30):4548-50. PubMed ID: 20855842
    [No Abstract]   [Full Text] [Related]  

  • 54. Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.
    Cameron DA; Camidge DR; Oyee J; Hirsch M
    Br J Cancer; 2008 Dec; 99(12):1984-90. PubMed ID: 19018261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer.
    Jiang W; He Z; Zhang T; Guo C; Zhao J; Zhu J; Wu J; Yu X; Chen C; Li J; Jiang J
    Immunotherapy; 2021 Jun; 13(8):661-668. PubMed ID: 33876668
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
    Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
    Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yang J; Han J; Tian M; Tian K; Liao W; Yan X
    Cancer Manag Res; 2020; 12():12905-12913. PubMed ID: 33364838
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer.
    Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Raaijmakers JA; Schellens JH
    Breast Cancer Res Treat; 2013 Jun; 139(2):489-95. PubMed ID: 23645005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.
    Telford C; Bertranou E; Large S; Phelps H; Ekman M; Livings C
    Pharmacoecon Open; 2019 Dec; 3(4):559-570. PubMed ID: 31025302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer.
    Xie Q; Zheng H; Li Q
    Breast Care (Basel); 2022 Jun; 17(3):237-243. PubMed ID: 35957949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.